Table 1

State of SLE patients included in the study

SLE patients

Quiescent disease (n = 33)

Active disease (n = 37)

No. male/female

5/28

7/30

Age (years), median (range)

45 (19 to 73)

37 (18 to 73)

SLEDAI, median (range)

2 (0 to 4)

10 (5 to 16) ***

Anti-dsDNA (E/ml), median (range)

25 (3 to 408)

230 (3 to 6,683) ***

C3(g/l), median (range)

0.99 (0.54 to 1.46)

0.73 (0.21 to 1.68) ***

C4 (g/l), median (range)

0.15 (0.06 to 0.28)

0.12 (0.02 to 0.30) *

CRP (g/I), median (range)

5 (5 to 27)

6 (1 to 92)

No. with/without treatment

31/2

29/8

Users of Prednisone (%) Dose (mg/day), median (range)

19 (58%) 10 (2.5 to 50)

21 (57%) 7.50 (2.5 to 100)

Users of Azathioprine (%) Dose (mg/day), median (range)

8 (24%) 150 (50 to 150)

5 (14%) 100 (75 to 150)

Users of Hydroxychloroquine (%) Dose (mg/day), median (range)

19 (58%) 400 (150 to 600)

16 (43%) 400 (200 to 1,200)

* Difference between quiescent and active SLE patients (* P < 0.05, ** P < 0.001, ***P < 0.0001).

Abdulahad et al. Arthritis Research & Therapy 2011 13:R71   doi:10.1186/ar3332